Correlation between adiponectin rs2241766 and rs266729 polymorphisms and risk of papillary thyroid cancer

Document Type : Original article

Authors

1 Department of Nutrition, School of Medicine, Zahedan University of Medical Sciences, Zahedan, Iran

2 Health Promotion Research Center, Department of Nutrition, School of Medicine, Zahedan University of Medical Sciences, Zahedan, Iran

3 Cellular and Molecular Research Center, Research Institue of Cellular and Molecular Sciences in Infectious Diseases, Zahedan University of Medical Sciences, Zahedan, Iran

4 Pregnancy Health Research Center, Department of Nutrition, School of Medicine, Zahedan University of Medical Sciences, Zahedan, Iran

5 Department of Clinical Biochemistry, School of Medicine, Zahedan University of Medical Sciences, Zahedan, Iran

6 Department of Endocrinology and Metabolism, Zahedan University of Medical Sciences, Zahedan, Iran

Abstract

About 60-80% of thyroid cancer (TC) cases are papillary thyroid cancer (PTC). Studies have shown that serum adiponectin levels are inversely related to the risk of TC and PTC. Aim of the present study was to evaluate the association between adiponectin rs2241766 and rs266729 polymorphisms and risk of PTC. 122 PTC patients and 128 healthy subjects were enrolled in the study. PCR-RFLP and ARMS-PCR methods were used for genotype analysis. The rs266729 polymorphism did not correlate with risk of PTC. As regard rs2241766 polymorphism, the frequency of the GG genotype did not have a significant difference between the two groups, although, PTC cases showed higher frequency of GT genotype compared to controls (OR=2.87, 95% CI=1.56-5.28, P=0.001). We observed a significant association between adiponectin rs2241766 polymorphism and PTC, however, our result showed no significant relationship between adiponectin rs266729 polymorphism and risk of PTC.

Keywords

References

  1. LiVolsi VA. Papillary thyroid carcinoma: an update. Mod Pathol 2011;24:S1-S9.
  2. Zeng R, Shou T, Yang KX, Shen T, Zhang JP, Zuo RX, Zheng YQ, Yan XM. Papillary thyroid carcinoma risk factors in the Yunnan plateau of southwestern China. Ther Clin Risk Manag 2016;12:1065-1074.
  3. Divella R, Daniele A, Mazzocca A, Abbate I, Casamassima P, Caliandro C, Ruggeri E, Naglieri E, Sabbà C, De Luca R. ADIPOQ rs266729 G/C gene polymorphism and plasmatic adipocytokines connect metabolic syndrome to colorectal cancer. J Cancer 2017;8:1000-1008.
  4. Abdullah MI, Junit SM, Ng KL, Jayapalan JJ, Karikalan B, Hashim OH. Papillary thyroid cancer: genetic alterations and molecular biomarker investigations. Int J Med Sci 2019; 16:450-460.
  5. Kwon H, Chang Y, Cho A, Ahn J, Park SE, Park CY, Lee WY, Oh KW, Park SW, Shin H, Ryu S, Rhee EJ. Metabolic obesity phenotypes and thyroid cancer risk: A cohort study. Thyroid 2019;29:349-358.
  6. Tumminia A, Vinciguerra F, Parisi M, Graziano M, Sciacca L, Baratta R, Frittitta L. Adipose tissue, obesity and adiponectin: Role in endocrine cancer risk. Int J Mol Sci 2019;20: 2863.
  7. Reneau J, Goldblatt M, Gould J, Kindel T, Kastenmeier A, Higgins R, Rengel L, Schoyer K, James R, Obi B, Moosreiner A, Nicholson K, Sahoo D, Kidambi B. Effect of adiposity on tissue-specific adiponectin secretion. PLoS One 2018;13:e0198889.
  8. Al-Harithy RN, Al-Zahrani MH. The adiponectin gene, ADIPOQ, and genetic susceptibility to colon cancer. Oncol Lett 2012;3:176-180.
  9. Diwan AG, Kuvalekar AA, Dharamsi S, Vora AM, Nikam VA, Ghadge AA. Correlation of serum adiponectin and leptin levels in obesity and type 2 diabetes mellitus. Indian J Endocrinol Metab 2018;22:93-99.
  10. Kwon H, Park SE, Yun JS, Park CY. Serum adiponectin and progranulin level in patients with benign thyroid nodule or papillary thyroid cancer. Endocrinol Metab (Seoul) 2020; 35:396-406.
  11. Okada-Iwabu M, Iwabu M, Yamauchi T, Kadowaki T. Structure and function analysis of adiponectin receptors toward development of novel antidiabetic agents promoting healthy longevity. Endocr J 2018;65:971-977.
  12. Cheng SP, Liu CL, Hsu YC, Chang YC, Huang SY, Lee JJ. Expression and biologic significance of adiponectin receptors in papillary thyroid carcinoma. Cell Biochem Biophys 2013;65:203-210.
  13. Johnson AD, Zhang Y, Papp AC, Pinsonneault JK, Lim JE, Saffen D, Dai Z, Wang D, Sadée W. Polymorphisms affecting gene transcription and mRNA processing in pharmaco-genetic candidate genes: detection through allelic expression imbalance in human target tissues. Pharmacogenet Genomics 2008;18:781-791.
  14. de Luis DA, Izaola O, Primo D, Aller R. Relation of a variant in adiponectin gene (rs266729) with metabolic syndrome and diabetes mellitus type 2 in adult obese subjects. Eur Rev Med Pharmacol Sci 2020;24:10646-10652.
  15. Li P, Liu H, Li C, Yang B, Kong Q, Zheng W, Li B, Jia B. An updated meta-analysis of the association between ADIPOQ rs2241766 polymorphism and colorectal cancer. Tumor Biol 2014;35:2491-2496.
  16. Suriyaprom K, Phonrat B, Tungtrongchitr R. Association of adiponectin gene-11377C>G polymorphism with adiponectin levels and the metabolic syndrome in Thais. Asia Pac J Clin Nutr 2014;23:167-73.
  17. Collins A, Ke X. Primer1: Primer design web service for tetra-primer ARMS-PCR. Bioinform J 2012;6:55-58.
  18. Nikiforova MN, Tseng GC, Steward D, Diorio D, Nikiforov YE. MicroRNA expression profiling of thyroid tumors: biological significance and diagnostic utility. J Clin Endocrinol Metab 2008;93:1600-1608.
  19. Firminger HI, Skelton FR. Carcinoma of the thyroid: papillary adenocarcinoma occurring in twins and a case of Hürthle cell carcinoma; tumor conference. J Kans méd Soc 1953;54: 427-432.
  20. Parida S, Siddharth S, Sharma D. Adiponectin, obesity, and cancer: Clash of the Bigwigs in health and disease. Int J Mol Sci 2019;20:2519.
  21. Booth A, Magnuson A, Fouts J, Foster M. Adipose tissue, obesity and adipokines: role in cancer promotion. Horm Mol Biol Clin Invest 2015;21:57-74.
  22. Mitsiades N, Pazaitou-Panayiotou K, Aronis KN, Moon HS, Chamberland JP, Liu X, Diakopoulos KN, Kyttaris V, Panagiotou V, Mylvaganam G, Tseleni-Balafouta S, Mantzoros CHS. Circulating adiponectin is inversely associated with risk of thyroid cancer: in vivo and in vitro studies. J Clin Endocrinol Metab 2011;96:2023-2028.
  23. Barrea L, Gallo M, Ruggeri RM, Giacinto PD, Sesti F, Prinzi N, Adinolfi V, Barocca V, Renzellii V, Muscogiuri V, Colao A, Baldelli R, Group E.O.L.O. Nutritional status and follicular-derived thyroid cancer: An update. Crit Rev Food Sci Nutr 2021;61:25-59.
  24. Shastry BS. SNPs: impact on gene function and phenotype. Method Mol Biol 2009;578:3-22.
  25. Yang Y, Zhang F, Ding R, Skrip L, Wang Y, Lei H, Hu D. ADIPOQ gene polymorphisms and cancer risk: a meta-analysis. Cytokine 2013;61:565-571.
  26. Zhou W, Liu Y, Zhong DW. Adiponectin (ADIPOQ) rs2241766 G/T polymorphism is associated with risk of cancer: evidence from a meta-analysis. Tumor Biol 2013;34:493-504.
  27. Hu X, Cui C, Sun T, Wang W. Associations between ADIPOQ rs2241766 SNP and breast cancer risk: a systematic review and a meta-analysis. Genes Environ 2021;43:48.
  28. Méndez-Hernández A, Gallegos-Arreola MP, Moreno-Macías H, Espinosa Fematt J, Pérez-Morales R. LEP rs7799039, LEPR rs1137101, and ADIPOQ rs2241766 and 1501299 polymorphisms are associated with obesity and chemotherapy response in Mexican women with breast cancer. Clin Breast Cancer 2017;17:453-462.
  29. Cui E, Deng A, Wang X, Wang B, Mao W, Feng X, Hua F. The role of adiponectin (ADIPOQ) gene polymorphisms in the susceptibility and prognosis of non-small cell lung cancer. Biochem Cell Biol 2011;89:308-313.
  30. Strulov Shachar S, Williams GR. The Obesity Paradox in Cancer-Moving Beyond BMI. Cancer Epidemiol Biomarkers Prev 2017;26:13-16.
  31. Neuhouser ML, Aragaki AK, Prentice RL, Manson JE, Chlebowski R, Carty CL, Ochs-Balcom HM, Thomson CY, Caan BJ, Tinker LF, Peragallo Urrutia R, Knudtson J, Anderson GL. Overweight, obesity, and postmenopausal invasive breast cancer risk: A secondary analysis of the women's health initiative randomized clinical trials. JAMA Oncol 2015;1:611-621.
  32. Taghizadeh N, Boezen HM, Schouten JP, Schröder CP, Elisabeth de Vries EG, Vonk JM. BMI and lifetime changes in BMI and cancer mortality risk. PLoS One 2015;10:e0125261.

Files

Share

How to cite

Statistics